Summary

for people ages 57-87 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's Disease (AD).

Official Title

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease

Keywords

Alzheimer's Disease Alzheimer Disease ABBV-8E12 ABBV-8E12 Dose 1 ABBV-8E12 Dose 2

Eligibility

You can join if…

Open to people ages 57-87

  • All subjects with early AD who complete Study M15-566 (NCT02880956), meet all inclusion criteria, and do not meet any

You CAN'T join if...

are eligible for enrollment

  • Subject was compliant during participation in Study M15-566 (NCT02880956).
  • Subject has an identified, reliable study partner who has frequent contact with the subject and who will provide information as to the subject's cognitive and functional abilities

Exclusion Criteria:

  • The subject has any significant change in his/her medical condition since participation in Study M15-566 (NCT02880956) that could interfere with the subject's participation in Study M15-570, could place the subject at increased risk, or could confound interpretation of study results
  • More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-566 (NCT02880956)
  • The subject is concurrently enrolled in another interventional clinical study involving a therapeutic agent with the exception of Study M15-566 (NCT02880956)

Locations

  • University of California, San /ID# 204011 not yet accepting patients
    San Francisco California 94143-0633 United States
  • Irvine Clinical Research /ID# 204000 not yet accepting patients
    Irvine California 92614 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03712787
Phase
Phase 2
Study Type
Interventional
Last Updated